Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Investment Income (2020 - 2025)

Historic Non Operating Investment Income for ImmunityBio (IBRX) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • ImmunityBio's Non Operating Investment Income rose 1496.11% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 2720.02%. This contributed to the annual value of $8.0 million for FY2024, which is 60512.82% up from last year.
  • As of Q3 2025, ImmunityBio's Non Operating Investment Income stood at $2.1 million, which was up 1496.11% from $1.2 million recorded in Q2 2025.
  • ImmunityBio's Non Operating Investment Income's 5-year high stood at $8.9 million during Q1 2021, with a 5-year trough of -$6.9 million in Q4 2021.
  • Over the past 5 years, ImmunityBio's median Non Operating Investment Income value was $857000.0 (recorded in 2022), while the average stood at $317000.0.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first crashed by 408724.83% in 2021, then soared by 503714.29% in 2024.
  • Quarter analysis of 5 years shows ImmunityBio's Non Operating Investment Income stood at -$6.9 million in 2021, then skyrocketed by 44.95% to -$3.8 million in 2022, then soared by 112.69% to $484000.0 in 2023, then soared by 145.25% to $1.2 million in 2024, then skyrocketed by 74.14% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $1.2 million for Q2 2025, and $887000.0 during Q1 2025.